Check out your Company Bowl for anonymous work chats.
The Supervisory Board of Sartorius AG resolved at its meeting today to approve the recommendation of the Executive Board to submit a proposal to the Annual General Shareholders’ Meeting on March 25, 2022, to pay dividends of 1.26 euros per preference share and 1.25 euros per ordinary share. As the terms of the members will expire at the end of this year’s AGM, the Supervisory Board also decided on its candidate proposals to be submitted to the Shareholders‘ Meeting for election of the board’s shareholder representatives. Read more:
The Supervisory Board of Sartorius AG proposes dividend of 1.26 euros per preference share
The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual General Shareholders' Meeting (AGM) on March 29, 2022, to pay a dividend of 1.26 euros per share for fiscal 2021, up from 0.68 euros per share a year earlier. As the terms of some members on the Board of Directors will expire at the end of this year’s AGM, the board also decided on its candidate proposals to be submitted to the AGM for election of these shareholder representatives.
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 1.26 euros per share to Annual Shareholders' Meeting
Sartorius closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin. The majority of the approximately 100 employees work at the Pompey site in eastern France and some in the USA, China, and India. As the acquisition is expected to generate additional non-organic sales revenue growth of around 1 percentage point in 2022, Sartorius has updated its sales revenue forecast for the current year.
Sartorius completes acquisition of Novasep's chromatography division
Sartorius is part of the solution in the fight against cancer 19 million people are being diagnosed with cancer every year. To realize the great promises of biopharmaceuticals for patients worldwide, Sartorius supports its customers in simplifying their workflows - so that innovative therapies and new medications reach patients faster. Learn more about how biologics can advance the detection and treatment of cancer on the Sartorius blog: http://ow.ly/GnuS50HMHcO
How Biopharmaceuticals Advance the Treatment of Cancer
Sartorius closes fiscal 2021 with 50 percent growth and a jump in profitability Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability. According to preliminary figures, the company achieved significant double-digit percentage growth in order intake, sales revenue and earnings, and expects dynamic development with double-digit growth in sales revenue and sustained high profitability in the current year as well.
Sartorius Preliminary Full-Year 2021 Results
In 2021, on average more than 300 new colleagues went through the onboarding programs at Sartorius' sites all over the world every month. Two of them are Elly Zhang and Zhaoqing Wang, who became part of the Shanghai team in fall. Learn more about their experiences and impressions as newbies and why they decided to join the company in the first place.
The Newbie Experience: Elly Zhang and Zhaoqing Wang
Within the scope of its "Donations Instead of Gifts" initiative, Sartorius is once again supporting the medical aid organization action medeor e.V. This year’s donations are being provided to a midwifery school in Sierra Leone, a country with particularly high maternal mortality. By improving midwifery training, the project is making an important and sustainable contribution to the promotion of healthcare for mothers and their newborns. Sartorius has engaged with action medeor in a partnership for the past six years. During this time, the company has supported projects in Northern Iraq, Yemen, DR Congo and Tanzania. Learn more about this partnership.
Partnership: action medeor e.V. | Sartorius
Sartorius is expanding its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH. The laboratory technology company based in Jena, Germany, develops, manufactures and markets solutions for the automated analysis, selection and isolation of cells. With these solutions, ALS enables life science customers to significantly reduce time to result and cost in cell line development and antibody discovery. Sartorius is initially purchasing 62.5 percent of the shares in ALS as of January 3, 2022. The remaining 37.5 percent will be acquired in 2026. ALS currently employs around 30 people and is expected to generate sales in the high single-digit million-euro area in 2021.
Sartorius strengthens its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions
At Sartorius IT, a team of software engineers and tech enthusiasts works together in an agile environment with a start-up culture. Together, they foster a digital customer experience: from building a digital ecosystem to the introduction of mixed reality. Learn more about how their work allows researchers to focus on achieving medical progress.
Part of the Solution: How Digital Customer Experience Simplifies Medical Progress
At Sartorius, Jens Heiduck and his team ensure the quality and regulatory compliance of each component that is used in Sartorius products - so that our biopharma customers can develop and produce medications reliably and safely. Find out how Jens' responsibilities and work environment have evolved over time and where the supplier quality management team is heading.
People at Sartorius: Jens Heiduck